PRPaula López Rivas

Paula López Rivas

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Paula López Rivas has a total of 52 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Conjugates of Cryptophycin and RGD or isoDGR Peptidomimetics for Targeted Drug Delivery

    by Adina Borbély, Eduard Figueras, Ana Martins, Lizeth Bodero, André Raposo Moreira Dias, Paula López Rivas, Arianna Pina, Daniela Arosio, Paola Gallinari, Marcel Frese, et al.

    RGD‐cryptophycin and isoDGR‐cryptophycin conjugates were synthetized by combining peptidomimetic integrin ligands and cryptophycin, a highly potent tubulin‐binding antimitotic agent across lysosomally cleavable Val‐Ala or uncleavable linkers. The conjugates were able to effectively inhibit binding of biotinylated vitronectin to integrin αvβ3, showing a binding affinity in the same range as that of the free ligands. The antiproliferative activity of the novel conjugates was evaluated on human melanoma cells M21 and M21‐L with different expression levels of integrin αvβ3, showing nanomolar potency of all four compounds against both cell lines. Conjugates containing uncleavable linker show reduced activity compared to the corresponding cleavable conjugates, indicating efficient intracellular drug release in the case of cryptophycin‐based SMDCs. However, no significant correlation between the in vitro biological activity of the conjugates and the integrin αvβ3 expression level was observed, which is presumably due to a non‐integrin‐mediated uptake. This reveals the complexity of effective and selective αvβ3 integrin‐mediated drug delivery.


  • β-Glucuronidase triggers extracellular MMAE release from an integrin-targeted conjugate

    by Paula López Rivas, Christoph Müller, Christian Breunig, Torsten Hechler, Andreas Pahl, Daniela Arosio, Laura Belvisi, Luca Pignataro, Alberto Dal Corso, Cesare Gennari

    A non-internalizing conjugate targeting αvβ3 integrin inhibits the proliferation of integrin-expressing cancer cells in the presence of β-glucuronidase.


  • Synthesis and Biological Evaluation of Paclitaxel Conjugates Involving Linkers Cleavable by Lysosomal Enzymes and αVβ3‐Integrin Ligands for Tumor Targeting

    by Paula López Rivas, Ivan Ranđelović, André Raposo Moreira Dias, Arianna Pina, Daniela Arosio, József Tóvári, Gábor Mező, Alberto Dal Corso, Luca Pignataro, Cesare Gennari


  • Open Access

    Synthesis and biological evaluation of RGD and isoDGR peptidomimetic-α-amanitin conjugates for tumor-targeting

    by Lizeth Bodero, Paula López Rivas, Barbara Korsak, Torsten Hechler, Andreas Pahl, Christoph Müller, Daniela Arosio, Luca Pignataro, Cesare Gennari, Umberto Piarulli

    RGD-α-amanitin and isoDGR-α-amanitin conjugates were synthesized by joining integrin ligands to α-amanitin via various linkers and spacers. The conjugates were evaluated for their ability to inhibit biotinylated vitronectin binding to the purified αVβ3 receptor, retaining good binding affinity, in the same nanomolar range as the free ligands. The antiproliferative activity of the conjugates was evaluated in three cell lines possessing different levels of αVβ3 integrin expression: human glioblastoma U87 (αVβ3+), human lung carcinoma A549 (αVβ3−) and breast adenocarcinoma MDA-MB-468 (αVβ3−). In the U87, in the MDA-MB-468, and partly in the A549 cancer cell lines, the cyclo[DKP-isoDGR]-α-amanitin conjugates bearing the lysosomally cleavable Val-Ala linker were found to be slightly more potent than α-amanitin. Apparently, for all these α-amanitin conjugates there is no correlation between the cytotoxicity and the expression of αVβ3 integrin. To determine whether the increased cytotoxicity of the cyclo[DKP-isoDGR]-α-amanitin conjugates is governed by an integrin-mediated binding and internalization process, competition experiments were carried out in which the conjugates were tested with U87 (αVβ3+, αVβ5+, αVβ6−, α5β1+) and MDA-MB-468 (αVβ3−, αVβ5+, αVβ6+, α5β1−) cells in the presence of excess cilengitide, with the aim of blocking integrins on the cell surface. Using the MDA-MB-468 cell line, a fivefold increase of the IC50 was observed for the conjugates in the presence of excess cilengitide, which is known to strongly bind not only αVβ3, but also αVβ5, αVβ6, and α5β1. These data indicate that in this case the cyclo[DKP-isoDGR]-α-amanitin conjugates are possibly internalized by a process mediated by integrins different from αVβ3 (e.g., αVβ5).


  • Open Access

    Development of Fluorescent Probes that Target Serotonin 5-HT2B Receptors

    by Jhonny Azuaje, Paula López, Alba Iglesias, Rocío A. de la Fuente, José M. Pérez-Rubio, Diego García, Tomasz Maciej Stępniewski, Xerardo García-Mera, José M. Brea, Jana Selent, et al.

    Some 5-HT2Bfluorescent probes were obtained by tagging 1-(2,5-dimethoxy-4-iodophenyl)-propan-2-amine (DOI) with a subset of fluorescent amines. Some of the resulting fluorescent ligands showed excellent affinity and selectivity profiles at the 5-HT2Breceptors (e.g.12b), while retain the agonistic functional behaviour of the model ligand (DOI). The study highlighted the most salient features of the structure-activity relationship in this series and these were substantiated by a molecular modelling study based on a receptor-driven docking model constructed on the basis of the crystal structure of the human 5-HT2Breceptor. One of the fluorescent ligands developed in this work, compound12i, specifically labelled CHO-K1 cells expressing 5-HT2Breceptors and not parental CHO-K1 cells in a concentration-dependent manner.12ienables imaging and quantification of specific 5-HT2Breceptor labelling in live cells by automated fluorescence microscopy as well as quantification by measurements of fluorescence intensity using a fluorescence plate reader.


  • Open Access

    Tumor Targeting with an isoDGR–Drug Conjugate

    by Simone Zanella, Simona Angerani, Arianna Pina, Paula López Rivas, Clelia Giannini, Silvia Panzeri, Daniela Arosio, Michele Caruso, Fabio Gasparri, Ivan Fraietta, et al.

    Herein we report the first example of an isoDGR–drug conjugate (2), designed to release paclitaxel selectively within cancer cells expressing integrin αVβ3. Conjugate 2 was synthesized by connecting the isoDGR peptidomimetic 5 with paclitaxel via the lysosomally cleavable Val–Ala dipeptide linker. Conjugate 2 displayed a low nanomolar affinity for the purified integrin αVβ3 receptor (IC50=11.0 nm). The tumor targeting ability of conjugate 2 was assessed in vitro in anti‐proliferative assays on two isogenic cancer cell lines characterized by different integrin αVβ3 expression: human glioblastoma U87 (αVβ3+) and U87 β3‐KO (αVβ3−). The isoDGR‐PTX conjugate 2 displayed a remarkable targeting index (TI=9.9), especially when compared to the strictly related RGD‐PTX conjugate 4 (TI=2.4).